|
EQS-News: Epigenomics AG / Key word(s): Personnel Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD) 26.01.2024 / 13:16 CET/CEST The issuer is solely responsible for the content of this announcement. Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD) Berlin, Germany, January 26, 2024 – Dr Heikki Lanckriet (PhD) has informed the competent bodies of Epigenomics AG (Frankfurt General Standard: ECX, the “Company”) that he resigned as a member of the Company’s Supervisory Board with effect as of 22 February 2024. The Supervisory Board will seek to find a suitable successor as member of the Company’s Supervisory Board and arrange for his/her appointment by court order in accordance with the statutory provisions. The chairwoman of the Supervisory Board, Dr Helge Lubenow, thanks Dr Heikki Lanckriet (PhD) for his commitment and dedication to the company and its employees. Contact: Investor Relations Note on forward-looking statements This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG’s actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
26.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Federal appeals court restricts access to abortion pill, attempting to revert back to FDA’s 2016 restrictions on the drug
The abortion drug mifepristone is once again facing court-imposed restrictions as a federal Fifth Circuit Court of Appeals ruled Wednesday that until final judgment, the
August 17, 2023